Literature DB >> 21383719

A siege of hepatitis: fighting a defiant virus.

Joshua T Schiffer1, John Scott, Lawrence Corey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21383719     DOI： 10.1038/nm0311-253

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  15 in total

1.  Rapid emergence of protease inhibitor resistance in hepatitis C virus.

Authors:  Libin Rong; Harel Dahari; Ruy M Ribeiro; Alan S Perelson
Journal:  Sci Transl Med       Date:  2010-05-05       Impact factor: 17.956

2.  Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.

Authors:  Edward J Gane; Stuart K Roberts; Catherine A M Stedman; Peter W Angus; Brett Ritchie; Rob Elston; David Ipe; Peter N Morcos; Linda Baher; Isabel Najera; Tom Chu; Uri Lopatin; M Michelle Berrey; William Bradford; Mark Laughlin; Nancy S Shulman; Patrick F Smith
Journal:  Lancet       Date:  2010-10-14       Impact factor: 79.321

3.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Authors:  John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

4.  Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

Authors:  Christophe Hézode; Nicole Forestier; Geoffrey Dusheiko; Peter Ferenci; Stanislas Pol; Tobias Goeser; Jean-Pierre Bronowicki; Marc Bourlière; Shahin Gharakhanian; Leif Bengtsson; Lindsay McNair; Shelley George; Tara Kieffer; Ann Kwong; Robert S Kauffman; John Alam; Jean-Michel Pawlotsky; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

5.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

Authors:  T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

6.  Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.

Authors:  Gary L Davis; Miriam J Alter; Hashem El-Serag; Thierry Poynard; Linda W Jennings
Journal:  Gastroenterology       Date:  2009-10-25       Impact factor: 22.682

7.  Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.

Authors:  Tara L Kieffer; Christoph Sarrazin; Janice S Miller; Martin W Welker; Nicole Forestier; Hendrik W Reesink; Ann D Kwong; Stefan Zeuzem
Journal:  Hepatology       Date:  2007-09       Impact factor: 17.425

8.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

9.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

10.  Hepatitis C virus infection of neuroepithelioma cell lines.

Authors:  Nicola F Fletcher; Jian Ping Yang; Michelle J Farquhar; Ke Hu; Christopher Davis; Qiuchen He; Kimberly Dowd; Stuart C Ray; Sophie E Krieger; Johan Neyts; Thomas F Baumert; Peter Balfe; Jane A McKeating; Flossie Wong-Staal
Journal:  Gastroenterology       Date:  2010-06-09       Impact factor: 22.682
View more
  2 in total

1.  Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay.

Authors:  Zongyi Hu; Xin Hu; Shanshan He; Hyung Joon Yim; Jingbo Xiao; Manju Swaroop; Cordelle Tanega; Ya-qin Zhang; Guanghui Yi; C Cheng Kao; Juan Marugan; Marc Ferrer; Wei Zheng; Noel Southall; T Jake Liang
Journal:  Antiviral Res       Date:  2015-10-26       Impact factor: 5.970

2.  Novel cell-based hepatitis C virus infection assay for quantitative high-throughput screening of anti-hepatitis C virus compounds.

Authors:  Zongyi Hu; Keng-Hsin Lan; Shanshan He; Manju Swaroop; Xin Hu; Noel Southall; Wei Zheng; T Jake Liang
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.